WEDNESDAY, March 19, 2025 (HealthDay News) — A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death linked to the treatment. The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, The Associated Press reported. However, the […]
The post Sarepta’s Gene Therapy Under Scrutiny After Patient Death first appeared on Physician’s Weekly.
